Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUMIT SAWHNEY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1548263353
CMS profile
341792
Location
CORAL SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$16,177.80

217 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $7,202.85 18
Athenex Pharmaceutical Division, LLC $4,025.00 4
Puma Biotechnology, Inc. $1,078.76 7
Janssen Biotech, Inc. $462.85 22
GlaxoSmithKline, LLC. $440.41 2
E.R. Squibb & Sons, L.L.C. $370.59 27
GENZYME CORPORATION $295.57 11
Amgen Inc. $214.19 12
PFIZER INC. $184.57 15
Seagen Inc. $153.64 9
Genentech USA, Inc. $130.23 8
Lilly USA, LLC $120.20 6
Foundation Medicine, Inc. $105.15 4
Merck Sharp & Dohme Corporation $100.07 6
Cardinal Health 110 LLC $100.00 1
IntrinsiQ Specialty Solutions, Inc. $100.00 1
Karyopharm Therapeutics Inc. $79.86 3
Bayer HealthCare Pharmaceuticals Inc. $75.82 5
Rigel Pharmaceuticals, Inc. $75.22 5
AbbVie Inc. $65.72 4
Dova Pharmaceuticals $62.56 4
Daiichi Sankyo Inc. $60.47 3
Celgene Corporation $59.15 3
Incyte Corporation $58.81 4
Janssen Pharmaceuticals, Inc $45.54 3
Novartis Pharmaceuticals Corporation $44.18 3
Takeda Pharmaceuticals U.S.A., Inc. $37.14 2
Verastem, Inc. $36.37 2
Astellas Pharma US Inc $35.79 2
Exelixis Inc. $35.66 2
Taiho Oncology, Inc. $25.06 2
Clovis Oncology, Inc. $23.91 1
BeiGene USA, Inc. $23.29 1
Boehringer Ingelheim Pharmaceuticals, Inc. $22.92 1
Coherus Biosciences Inc. $21.61 1
ARRAY BIOPHARMA INC $20.05 1
Deciphera Pharmaceuticals Inc. $20.00 1
Kyowa Kirin, Inc. $19.76 1
Alexion Pharmaceuticals, Inc. $18.69 1
Acceleron Pharma, Inc. $18.13 1
Ipsen Biopharmaceuticals, Inc $16.32 1
Sun Pharmaceutical Industries Inc. $16.14 1
Eisai Inc. $14.50 1
Octapharma USA, Inc. $13.02 1
Agios Pharmaceuticals, Inc. $12.96 1
Aurobindo Pharma USA, Inc. $12.65 1
Teva Pharmaceuticals USA, Inc. $11.26 1
Advanced Accelerator Applications $11.16 1

Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUMIT SAWHNEY

NPI 1548263353 · CMS profile ID 341792

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CORAL SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548263353?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUMIT SAWHNEY, NPI 1548263353, CMS profile ID 341792. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548263353?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SUMIT SAWHNEY, NPI 1548263353, CMS profile ID 341792. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548263353?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SUMIT SAWHNEY, NPI 1548263353, CMS profile ID 341792, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1548263353?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

217 matching records · $16,177.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 217 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 217.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $19.7106/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736173807 CMS
Incyte Corporation $11.4106/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745807441 CMS
Janssen Biotech, Inc. $10.7006/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440361 CMS
Amgen Inc. $17.2706/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741325021 CMS
Amgen Inc. $15.3206/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741325015 CMS
Daiichi Sankyo Inc. $18.5506/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739486883 CMS
Puma Biotechnology, Inc. $16.8606/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750538081 CMS
PFIZER INC. $11.8906/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743453247 CMS
E.R. Squibb & Sons, L.L.C. $12.2006/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805163 CMS
Eisai Inc. $14.5006/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751343277 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.6706/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713635145 CMS
E.R. Squibb & Sons, L.L.C. $2.9506/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805179 CMS
E.R. Squibb & Sons, L.L.C. $14.5706/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805183 CMS
Taiho Oncology, Inc. $13.1906/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724401725 CMS
Incyte Corporation $14.1205/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745807437 CMS
Janssen Biotech, Inc. $11.1305/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440359 CMS
Karyopharm Therapeutics Inc. $26.4505/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751736843 CMS
Janssen Biotech, Inc. $21.0805/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440337 CMS
Janssen Biotech, Inc. $30.8905/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440339 CMS
Foundation Medicine, Inc. $27.1305/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 714558037 CMS
GlaxoSmithKline, LLC. $15.4105/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738732333 CMS
GENZYME CORPORATION $24.9205/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744147807 CMS
Janssen Biotech, Inc. $17.7105/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440371 CMS
Seagen Inc. $12.5505/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732443809 CMS
AstraZeneca Pharmaceuticals LP $1,365.0005/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735844135 CMS
Cardinal Health 110 LLC $100.0005/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 717768765 CMS
E.R. Squibb & Sons, L.L.C. $14.7505/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805167 CMS
E.R. Squibb & Sons, L.L.C. $2.7305/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805169 CMS
AstraZeneca Pharmaceuticals LP $19.7505/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736014536 CMS
Clovis Oncology, Inc. $23.9105/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722232477 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.9705/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713624523 CMS
GENZYME CORPORATION $12.9605/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744147795 CMS
Janssen Pharmaceuticals, Inc $16.0505/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440325 CMS
Exelixis Inc. $16.2004/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737175551 CMS
E.R. Squibb & Sons, L.L.C. $10.6104/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805155 CMS
GENZYME CORPORATION $13.1604/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744147789 CMS
Taiho Oncology, Inc. $11.8704/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724401711 CMS
Puma Biotechnology, Inc. $12.4104/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750540885 CMS
Seagen Inc. $16.6504/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732443793 CMS
Amgen Inc. $12.5604/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741325013 CMS
AstraZeneca Pharmaceuticals LP $19.4404/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736183623 CMS
Genentech USA, Inc. $17.8304/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743115897 CMS
Celgene Corporation $16.7304/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805225 CMS
Dova Pharmaceuticals $18.2204/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752352289 CMS
Sun Pharmaceutical Industries Inc. $16.1404/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728271797 CMS
Genentech USA, Inc. $15.4304/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743115903 CMS
E.R. Squibb & Sons, L.L.C. $17.6804/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727805153 CMS
Janssen Biotech, Inc. $17.8404/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440341 CMS
Janssen Biotech, Inc. $10.6804/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719440343 CMS
Incyte Corporation $19.9604/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745807427 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20,014.17 350
PY2020 $16,177.80 217
PY2021 $20,752.98 208
PY2022 $18,768.89 239
PY2023 $9,674.24 144
PY2024 $9,539.17 40
PY2025 $7,888.12 101

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $206,255.96 9
PY2024 Principal investigator $160,856.21 10
PY2023 Recipient $78,386.10 5
PY2023 Principal investigator $157,976.35 15
PY2022 Recipient $5,836.00 1
PY2022 Principal investigator $57,850.69 13
PY2021 Principal investigator $252,909.97 11
PY2020 Principal investigator $4,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

9 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,664.20 11/03/2025 Non-covered Recipient Entity
Advanced Research Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235999279
Principal investigator 1 GENZYME CORPORATION $17,754.00 10/30/2025 Non-covered Recipient Entity
Advanced Research LLC
A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226089070
Principal investigator 1 Amgen Inc. $3,797.50 09/23/2025 Non-covered Recipient Entity
CORAZON USA, LLC
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients No dispute reported 06/30/2026 1246640523
Principal investigator 1 GENZYME CORPORATION $13,838.00 05/27/2025 Non-covered Recipient Entity
Advanced Research LLC
A Phase 3, multicenter, randomized, double-bline, placebo controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (WAIHA) No dispute reported 06/30/2026 1226089031
Principal investigator 1 Eli Lilly and Company $765.54 05/08/2025 Non-covered Recipient Entity
ADVANCED RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA No dispute reported 06/30/2026 1187876085
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,687.39 03/19/2025 Non-covered Recipient Entity
Advanced Research
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235999319
Principal investigator 1 Eli Lilly and Company $12,778.75 02/24/2025 Non-covered Recipient Entity
ADVANCED RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA No dispute reported 06/30/2026 1187875883
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,016.39 01/27/2025 Non-covered Recipient Entity
Advanced Research
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235999317
Principal investigator 1 Celgene Corporation $110,954.19 01/10/2025 Non-covered Recipient Entity
Advanced Research Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222306425